Krista Hill, MD
Family Medicine · Council Bluffs, IANPI 1578571188
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.6%), speaking fees and education — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by AbbVie at 53.0% of the total. Reporting peaked in 2022 at $4,176 and has fallen 92.7% since, to $305 in 2025. Among family medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $29.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- AstraZeneca$521
- Amgen$431
- Aimmune Therapeutics, Inc.$394
- Pfizer$326
- Novo Nordisk$215
- plus $2K from 33 others
What the payments were for
- Speaking & faculty fees$3,36040%
- Food & beverage$5,00760%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 68 | $4,452 |
| AstraZeneca | 23 | $521 |
| Amgen | 32 | $431 |
| Aimmune Therapeutics, Inc. | 3 | $394 |
| Pfizer | 25 | $326 |
| Novo Nordisk | 14 | $215 |
| Gilead | 8 | $203 |
| Novartis | 11 | $167 |
| Boehringer Ingelheim | 14 | $156 |
| Johnson & Johnson | 11 | $154 |
| Sanofi-aventis U.S. LLC | 9 | $146 |
| Nestle Healthcare Nutrition Inc. | 1 | $144 |
| Abbott | 8 | $137 |
| Abiomed | 1 | $132 |
| Astellas Pharma US Inc | 8 | $117 |
| Bayer | 5 | $88 |
| E.r. Squibb & Sons, L.L.C. | 5 | $69 |
| Teva Pharmaceuticals USA, Inc. | 4 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $51 |
| Exact Sciences | 2 | $45 |
| Lilly USA, LLC | 3 | $40 |
| Lexicon Pharmaceuticals, Inc. | 2 | $30 |
| Insulet Corporation | 2 | $30 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Merck | 2 | $28 |
| Mylan Specialty L.p. | 2 | $27 |
| Mannkind Corporation | 2 | $24 |
| Corcept Therapeutics | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Organon | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,396 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 151 | $178,978 |
| TrulicityDulaglutide | 54 | $66,425 |
| OzempicSemaglutide | 49 | $53,681 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $37,078 |
| EliquisApixaban | 58 | $32,535 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $30,390 |
| XareltoRivaroxaban | 25 | $25,513 |
| JardianceEmpagliflozin | 25 | $23,471 |
| FarxigaDapagliflozin Propanediol | 28 | $22,712 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $18,379 |
| QuliptaAtogepant | 14 | $16,484 |
| MyrbetriqMirabegron | 22 | $14,737 |
| JanuviaSitagliptin Phosphate | 16 | $13,676 |
| Varenicline Tartrate | 24 | $9,865 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $9,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $40 | $245,404205 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $521 | $63,04286 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $12 | $55,55884 claims |
| Novo NordiskOzempic | $215 | $53,68149 claims |
| PfizerEliquis | $326 | $32,53558 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $156 | $31,88138 claims |
| Johnson & JohnsonXarelto | $154 | $25,51325 claims |
| AbbVieQulipta | $4,452 | $16,48414 claims |
| Astellas Pharma US IncMyrbetriq | $117 | $14,73722 claims |
| MerckJanuvia | $28 | $13,67616 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $18 | $5,38411 claims |
| Sanofi-aventis U.S. LLCLantus | $146 | $3,08218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Council Bluffs
- Kevin SheppardCouncil Bluffs$20K
- Kavish RohatgiCouncil Bluffs$14K
- Mel RocaCouncil Bluffs$13K
- Joseph WanzekCouncil Bluffs$13K
- James WhalenCouncil Bluffs$11K
- Barclay MonasterCouncil Bluffs$10K
- Jamie ArmbrusterCouncil Bluffs$7K
- Thomas McElderryCouncil Bluffs$7K
- Pranith SurabhiCouncil Bluffs$7K
- Christian JonesCouncil Bluffs$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.